C.R. Bard Inc. (NYSE:BCR) announced a quarterly dividend on Wednesday, October 12th. Stockholders of record on Monday, October 24th will be given a dividend of 0.26 per share on Friday, November 4th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.48%.

Shares of C.R. Bard (NYSE:BCR) opened at 217.82 on Thursday. The stock has a market cap of $16.00 billion, a price-to-earnings ratio of 50.66 and a beta of 0.50. C.R. Bard has a 1-year low of $172.21 and a 1-year high of $239.43. The stock’s 50 day moving average price is $222.08 and its 200-day moving average price is $220.63.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The firm had revenue of $931.50 million for the quarter, compared to analysts’ expectations of $915.22 million. During the same period in the previous year, the firm earned $2.27 EPS. The business’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities research analysts forecast that C.R. Bard will post $10.17 earnings per share for the current year.

Dividend History for C.R. Bard (NYSE:BCR)

In related news, Chairman Timothy M. Ring sold 92,293 shares of the business’s stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $227.81, for a total transaction of $21,025,268.33. Following the completion of the transaction, the chairman now owns 145,876 shares in the company, valued at approximately $33,232,011.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Betty D. Larson sold 4,032 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $225.33, for a total value of $908,530.56. Following the transaction, the vice president now owns 10,298 shares of the company’s stock, valued at approximately $2,320,448.34. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Cleararc Capital Inc. boosted its stake in shares of C.R. Bard by 0.9% in the second quarter. Cleararc Capital Inc. now owns 1,795 shares of the company’s stock valued at $422,000 after buying an additional 16 shares in the last quarter. First Allied Advisory Services Inc. boosted its stake in shares of C.R. Bard by 6.6% in the second quarter. First Allied Advisory Services Inc. now owns 1,098 shares of the company’s stock valued at $258,000 after buying an additional 68 shares in the last quarter. Veritable L.P. boosted its stake in shares of C.R. Bard by 3.6% in the second quarter. Veritable L.P. now owns 2,957 shares of the company’s stock valued at $695,000 after buying an additional 102 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of C.R. Bard by 0.7% in the second quarter. Mackenzie Financial Corp now owns 16,514 shares of the company’s stock valued at $3,883,000 after buying an additional 114 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of C.R. Bard by 9.7% in the second quarter. Pacer Advisors Inc. now owns 1,371 shares of the company’s stock valued at $322,000 after buying an additional 121 shares in the last quarter. Institutional investors own 87.90% of the company’s stock.

Several brokerages recently issued reports on BCR. Jefferies Group reissued a “hold” rating and set a $237.00 target price on shares of C.R. Bard in a research note on Tuesday, September 27th. Wells Fargo & Co. raised C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Evercore ISI began coverage on C.R. Bard in a research note on Thursday, September 15th. They set a “buy” rating and a $235.00 target price on the stock. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Finally, Morgan Stanley reissued a “hold” rating and set a $240.00 target price on shares of C.R. Bard in a research note on Thursday, July 28th. Thirteen analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $233.00.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.